Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to offer
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNAediting technology platform, today announced the Annual …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Key program features and updates: ProQR to … Axiomer®: ProQR will introduce its novel, proprietary RNAediting platform technology. Art Levin, Ph.D., an …